Financial reports
20-F
2023 FY
Annual report (foreign)
21 Mar 24
20-F
2022 FY
Annual report (foreign)
22 Mar 23
20-F
2022 FY
Annual report (foreign)
24 Mar 22
20-F
2020 FY
Annual report (foreign)
25 Mar 21
20-F
2019 FY
Annual report (foreign)
29 Apr 20
20-F/A
2018 FY
Annual report (foreign) (amended)
29 Mar 19
20-F
2018 FY
Annual report (foreign)
28 Mar 19
20-F
2017 FY
Annual report (foreign)
29 Mar 18
Current reports
6-K
Report of Foreign Private Issuer
25 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Corporate Presentation March 2024
21 Mar 24
6-K
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
21 Mar 24
6-K
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
25 Jan 24
6-K
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4 Jan 24
6-K
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
6 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
11 Sep 23
6-K
Current report (foreign)
30 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 Jul 23
F-3
Shelf registration (foreign)
30 Jun 23
424B5
Prospectus supplement for primary offering
13 Apr 23
424B5
Prospectus supplement for primary offering
11 Apr 23
424B5
Prospectus supplement for primary offering
26 Feb 21
424B5
Prospectus supplement for primary offering
24 Feb 21
S-8
Registration of securities for employees
30 Jul 20
424B5
Prospectus supplement for primary offering
20 Jul 20
F-3/A
Shelf registration (foreign) (amended)
16 Jul 20
F-3
Shelf registration (foreign)
8 Jul 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
6 Jul 23
EFFECT
Notice of effectiveness
20 Jul 20
CORRESP
Correspondence with SEC
16 Jul 20
UPLOAD
Letter from SEC
15 Jul 20
EFFECT
Notice of effectiveness
4 May 18
CORRESP
Correspondence with SEC
2 May 18
CORRESP
Correspondence with SEC
2 May 18
UPLOAD
Letter from SEC
1 May 18
Ownership
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
24 Apr 23
SC 13G
TANG CAPITAL PARTNERS LP
17 Apr 23
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 23
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 22
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
8 Mar 21
SC 13G
GREAT POINT PARTNERS LLC
8 Mar 21
SC 13G/A
BAKER BROS. ADVISORS LP
16 Feb 21
SC 13D
Beneficial ownership report
18 Feb 20
SC 13D
InflaRx N.V.
18 Feb 20